91 results about "Cns disease" patented technology

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3α-OH-5α-pregnan-20-one, or 3α-OH-5β-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder. In another embodiment, a method of treating a CNS disorder can comprise orally administering to the subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of 3α-OH-5α-pregnan-20-one, or 3α-OH-5β-pregnan-20-one, or both that is sufficient to treat the CNS disorder.

The invention relates to a heterocyclic fused gamma-carboline compound, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and a pharmaceutical composition containing the heterocyclic fused gamma-carboline compound. The compounds, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, and pharmaceutical compositions have agonistic activity against 5-HT receptors, and can be used as 5-HT receptor agonists for the prevention or treatment of diseases or various CNS diseases or conditions related to the activity or expression level of 5-HT receptors. # imgabs0 #

Provided herein are compounds and conjugates comprising transferrin receptor binding protein, pharmaceutical compositions comprising such conjugates, and methods of treating CNS diseases (e.g., neurodegenerative disease) using such conjugates.

Described herein are methods relating to the treatment of certain diseases with an agonist of Mfsd2A, and the treatment of certain other diseases with an inhibitor of Mfsd2A.

The present invention provides a conjugate comprising: (a) a CNS targeting ligand, (b) a hydrophilic polymer of polyethylene glycol (PEG), polylactic acid (PLA), polylactic acid-co-glycolic acid (PLGA), or glucan, and (c) a flavonoid. The present invention also provides a micelle nanoparticle composition comprising: (a) an outer shell comprising the conjugate, optionally (b) an inner shell comprising oligomeric (-)-epigallocatechin gallate (OEGCG), and optionally (c) a CNS disease treatment molecule encapsulated in the inner shell. The invention also provides a method of treating a CNS disease by administering to a subject an effective amount of a nanoparticle composition of the invention. The CNS targeting ligand targets a CNS tissue and delivers an active ingredient to the CNS tissue for treating a CNS pathological condition.

The disclosure provides methods for the treatment of cerebral cavernous malformation and Devic's disease with ROCK2 inhibitors. The disclosure also provides pharmaceutical formulations for the oral administration of ROCK2 inhibitors for use in the treatment of cerebral cavernous malformation and Devic's disease.

The present disclosure relates to compositions, kits, and methods of treating CNS diseases and disorders using a combination of a muscarinic receptor positive modulator and an NMDA receptor positive allosteric modulator.

Provided herein are proteins comprising TfR binding protein, conjugates comprising such TfR binding proteins, e.g., TfR binding proteins-dsRNA conjugates, pharmaceutical compositions comprising TfR binding proteins or conjugates, and methods of treating CNS diseases (e.g., neurodegenerative disease) using TfR binding proteins or conjugates. Also included are methods of treating or reducing pain.

Provided herein are improved rAAV (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of ocular disorders or CNS disorders wherein the rAAV comprise one or more substitutions of amino acids that interact with heparan sulfate proteoglycan. The invention provides methods for improved transduction of retinal cells and methods for treating ocular diseases with improved compositions of rAAV particles. Further provided herein are improved recombinant adeno-associated virus (rAAV) (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of disorders of the CNS. The invention provides methods for delivering the rAAV to the CNS, methods for treating disorders of the CNS with improved compositions of rAAV particles, and kits for delivering the rAAV to the CNS and / or treating a CNS disorder.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

Provided herein are proteins comprising one monovalent human TfR binding domain ("human TfR binding proteins"), conjugates comprising such human TfR binding proteins, e.g., human TfR binding proteins-dsRNA conjugates, pharmaceutical compositions comprising human TfR binding proteins or conjugates, and methods of treating CNS diseases (e.g., neurodegenerative disease such as neurodegenerative synucleinopathy or tauopathy) using human TfR binding proteins or conjugates.

The present application relates to cost-effective, practical and scalable synthetic routes for the syntheses for psilocybin (Formula I) and its major metabolite psilocybin (Formula II) and their pharmaceutically acceptable salts. These compounds are useful for the treatment or prevention of mental health disorders, such as major depressive disorder, anxiety and addiction disorders, among others CNS disorders.

Disclosed herein are certain therapeutic substituted heterocyclic bridged ring compounds, including substituted morpholine, thiomorpholine, and piperidine compounds and their homologues, having various advantages over current compounds used in certain methods of drug-assisted therapy, such as MDMA, together with pharmaceutical compositions containing such compounds, and methods of their use to treat mental health disorders and CNS disorders.

Described herein are BBB-transporting fusion proteins, polynucleotides encoding the fusion proteins and mammalian cells genetically modified to express and secrete the fusion proteins, as well as compositions, implantable devices and device preparations comprising the fusion proteins or genetically modified cells secreting the fusion proteins, and methods of making and using the same for treating various CNS diseases and conditions, e.g., any mucopolysaccharidosis type with CNS manifestations.

To provide novel analogs of cytisine, and their use in medicine, for example in the treatment of addiction, as well as improved synthetic methods for the preparation of analogs of cytisine.SOLUTION: Disclosed are novel analogs of cytisine, a process for their preparation, pharmaceutical compositions containing them, and their use in the prevention of or treatment of CNS disorders including addictive disorders. The chemical structure of the novel cytisine analogs of the present invention is illustrated in the following chemical formula.SELECTED DRAWING: None

Disclosed are N-(phenyl)-1H-indole-3-sulfonanmide and N-(phenyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide derivatives of formula I substituted at the 1- and 6-positions of the 1H-indole or 1H-pyrrolo[2,3-b]pyridine moiety, as well as structurally related compounds (e.g. the N-pyridin-2-yl and the N-pyridin-3-yl analogues thereof). The present compounds have GPR17 modulating properties which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating disorders such as multiple sclerosis.

An electroencephalography (EEG) system comprises: an EEG device; a display; one or more processors; a memory; and one or more programs, wherein the one or more programs are stored in the memory and configured to be executed by the one or more processors, the one or more programs including instructions for: receiving measurement data; extracting, from the measurement data, a first set of features and a second set of features; inputting the first set of features and the second set of features into a first treatment-specific machine-learning model and a second treatment-specific machine-learning model, respectively; generating a data structure based on the predicted treatment responses; and rendering, on the display, the generated data structure to provide the predicted treatment responses to the first candidate treatment of the CNS disease and the second candidate treatment of the CNS disease.

This invention describes agents, methods, compositions, kits and uses of medicaments for inhibiting or suppressing expression of TGF-β2 for treating or ameliorating the symptoms of a CNS disease in a human subject or animal, including diffuse midline glioma (DMG) and K27M GBM. The agents may be used in combination with cancer drugs. These purposes can be achieved with formulations of agents for inhibiting or suppressing expression of TGF-β2. More particularly, this invention discloses compositions, methods and uses for antisense oligonucleotides against TGF-β2, in a regimen for CNS disease. This invention further describes novel devices and methods for delivering a pharmaceutical composition by intracranial infusion.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI). vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

The present disclosure provides methods for preventing, treating, or delaying progression of neuroinflammatory CNS conditions, e.g., Alzheimer's disease, by administration of an agent that inhibits macrophage migration inhibitory factor (MIF)-CD74 signaling. In some embodiments the agent to be administered is a MIF-binding protein such as a MIF antibody. In other embodiments disclosed herein the agent is a targeting polynucleotide against MIF or CD74.

Provided herein are compounds useful for treating cognitive dysfunction and negative symptoms associated with CNS disorders. In aspects, a compound of formula (I') is [Image disponible dans le document PDF, Image available in the PDF document] and the others are independently CH, CF, CCF<com:Sub>3< / com:Sub>, CCH<com:Sub>3< / com:Sub> or COCF<com:Sub>3< / com:Sub>; R<com:Sup>1< / com:Sup> is phenyl, CN, F, OCF<com:Sub>3< / com:Sub>, C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkoxy or C<com:Sub>1< / com:Sub>-C<com:Sub>5< / com:Sub> alkyl; R<com:Sup>2< / com:Sup> is H, C<com:Sub>1< / com:Sub>-C<com:Sub>5< / com:Sub> alkyl or C<com:Sub>1< / com:Sub>-C<com:Sub>5< / com:Sub> alkoxy; R<com:Sup>3< / com:Sup> is H or CH<com:Sub>3< / com:Sub>; or R<com:Sup>1< / com:Sup> and R<com:Sup>2< / com:Sup> together represent an optionally substituted 5 or 6-membered O-containing heterocyclylene, optionally substituted 5 or 6-membered O-containing heteroarylene, or optionally substituted 5 or 6-membered arylene; and R<com:Sup>4< / com:Sup> and R<com:Sup>5< / com:Sup> are independently H or C<com:Sub>1< / com:Sub>- C<com:Sub>4< / com:Sub> alkyl, or R<com:Sup>4< / com:Sup> and R<com:Sup>5< / com:Sup> together represent an optionally substituted 4-7 membered cycloalkylene or optionally substituted 5-7 membered heterocycylene. Also provided are medicaments, compositions and therapuetic uses thereof.

The present disclosure provides compositions of (4R,5R)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one (Compound 1). Crystal and solvate forms of the compound are also provided, as well as formulations comprising the compound. Methods of using the compounds and administering formulations to a subject in need thereof to treat or prevent CNS disorders, such as Alzheimer's disease, are provided.

The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3′5′-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.

To provide compositions and methods to improve delivery of gene therapy vectors and therapeutics across the BBB to provide more effective treatment for a variety of CNS conditions.SOLUTION: Compositions and methods for delivering effector entities to the CNS of a subject are provided. Engineered AAV capsids that bind GPI-anchored proteins on the BBB are provided as well as methods for their use, including delivery of gene therapy and effector entities. Also provided are methods for reducing the infectivity of the CNS by an AAV.SELECTED DRAWING: None

The present disclosure concerns a microglia progenitor cell derived from bone marrow and / or placental stromal cells and / or umbilical cord stromal cell and methods for their isolation; as well as use of said cells for therapy of disorders of the CNS.

An electroencephalography (EEG) system comprises: an EEG device; a display; one or more processors; a memory; and one or more programs, wherein the one or more programs are stored in the memory and configured to be executed by the one or more processors, the one or more programs including instructions for: receiving measurement data; extracting, from the measurement data, a first set of features and a second set of features; inputting the first set of features and the second set of features into a first treatment-specific machine-learning model and a second treatment-specific machine-learning model, respectively; generating a data structure based on the predicted treatment responses; and rendering, on the display, the generated data structure to provide the predicted treatment responses to the first candidate treatment of the CNS disease and the second candidate treatment of the CNS disease.

Aspects of the disclosure related to peripheral blocker compounds for use in reducing peripheral side effects of anti-CNS disease drugs.